| Dr Jeffrey A Biller, MD | |
|
40 Second Ave, Ste 340 Mass General West, Waltham, MA 02451 | |
| (781) 466-8988 | |
| (781) 466-8987 |
| Full Name | Dr Jeffrey A Biller |
|---|---|
| Gender | Male |
| Speciality | Gastroenterology |
| Experience | 48 Years |
| Location | 40 Second Ave, Waltham, Massachusetts |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1467443259 | NPI | - | NPPES |
| 700983 | Other | MA | TUFTS HEALTH PLAN |
| J02176 | Other | MA | BCBS MA |
| 6171737 | Medicaid | MA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208000000X | Pediatrics | 47848 (Massachusetts) | Secondary |
| 2080P0206X | Pediatrics - Pediatric Gastroenterology | 47848 (Massachusetts) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Massachusetts General Physicians Organization Inc | 2466365820 | 3085 |
News Archive
Actinium Pharmaceuticals, Inc. a biotechnology company focused on developing innovative, alpha particle radiotherapy targeted cancer treatments addressing major unmet medical needs, today announced that it has successfully treated the first cohort of patients in a Phase I/II study of Actimab-A in Acute Myeloid Leukemia (AML) clinical trial. Patients were treated at Memorial Sloan Kettering Cancer Center in New York City.
The death rate from drug- and alcohol-related causes in people who've had Roux-en-Y gastric bypass surgery is nearly triple that of the general public, according to University of Pittsburgh research published today in Surgery for Obesity and Related Diseases, the journal of the American Society for Metabolic and Bariatric Surgery.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Six government drug control laboratories in the Middle East and North Africa will join together with the United States Pharmacopeial Convention in an effort to improve their capabilities to test the quality of drugs. The MENA Regional Laboratory Network aims to promote communication and exchange of information among participating countries, strengthen the performance and technical skill of the laboratories and their personnel, harmonize methods that facilitate approval of drugs across countries in the region, and help eliminate substandard and counterfeit drugs.
Researchers from The Australian National University have identified unique molecular signals in the body that could hold the key to developing a supplement capable of administering the health benefits of exercise to patients incapable of physical activity.
› Verified 2 days ago
| Entity Name | Massachusetts General Physicians Organization Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801874573 PECOS PAC ID: 2466365820 Enrollment ID: O20031111000434 |
News Archive
Actinium Pharmaceuticals, Inc. a biotechnology company focused on developing innovative, alpha particle radiotherapy targeted cancer treatments addressing major unmet medical needs, today announced that it has successfully treated the first cohort of patients in a Phase I/II study of Actimab-A in Acute Myeloid Leukemia (AML) clinical trial. Patients were treated at Memorial Sloan Kettering Cancer Center in New York City.
The death rate from drug- and alcohol-related causes in people who've had Roux-en-Y gastric bypass surgery is nearly triple that of the general public, according to University of Pittsburgh research published today in Surgery for Obesity and Related Diseases, the journal of the American Society for Metabolic and Bariatric Surgery.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Six government drug control laboratories in the Middle East and North Africa will join together with the United States Pharmacopeial Convention in an effort to improve their capabilities to test the quality of drugs. The MENA Regional Laboratory Network aims to promote communication and exchange of information among participating countries, strengthen the performance and technical skill of the laboratories and their personnel, harmonize methods that facilitate approval of drugs across countries in the region, and help eliminate substandard and counterfeit drugs.
Researchers from The Australian National University have identified unique molecular signals in the body that could hold the key to developing a supplement capable of administering the health benefits of exercise to patients incapable of physical activity.
› Verified 2 days ago
| Entity Name | The General Hospital Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023049236 PECOS PAC ID: 6507803806 Enrollment ID: O20080313000351 |
News Archive
Actinium Pharmaceuticals, Inc. a biotechnology company focused on developing innovative, alpha particle radiotherapy targeted cancer treatments addressing major unmet medical needs, today announced that it has successfully treated the first cohort of patients in a Phase I/II study of Actimab-A in Acute Myeloid Leukemia (AML) clinical trial. Patients were treated at Memorial Sloan Kettering Cancer Center in New York City.
The death rate from drug- and alcohol-related causes in people who've had Roux-en-Y gastric bypass surgery is nearly triple that of the general public, according to University of Pittsburgh research published today in Surgery for Obesity and Related Diseases, the journal of the American Society for Metabolic and Bariatric Surgery.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Six government drug control laboratories in the Middle East and North Africa will join together with the United States Pharmacopeial Convention in an effort to improve their capabilities to test the quality of drugs. The MENA Regional Laboratory Network aims to promote communication and exchange of information among participating countries, strengthen the performance and technical skill of the laboratories and their personnel, harmonize methods that facilitate approval of drugs across countries in the region, and help eliminate substandard and counterfeit drugs.
Researchers from The Australian National University have identified unique molecular signals in the body that could hold the key to developing a supplement capable of administering the health benefits of exercise to patients incapable of physical activity.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jeffrey A Biller, MD Po Box 9142, Mass General Physician Organization, Charlestown, MA 02129-9142 Ph: (781) 466-8967 | Dr Jeffrey A Biller, MD 40 Second Ave, Ste 340 Mass General West, Waltham, MA 02451 Ph: (781) 466-8988 |
News Archive
Actinium Pharmaceuticals, Inc. a biotechnology company focused on developing innovative, alpha particle radiotherapy targeted cancer treatments addressing major unmet medical needs, today announced that it has successfully treated the first cohort of patients in a Phase I/II study of Actimab-A in Acute Myeloid Leukemia (AML) clinical trial. Patients were treated at Memorial Sloan Kettering Cancer Center in New York City.
The death rate from drug- and alcohol-related causes in people who've had Roux-en-Y gastric bypass surgery is nearly triple that of the general public, according to University of Pittsburgh research published today in Surgery for Obesity and Related Diseases, the journal of the American Society for Metabolic and Bariatric Surgery.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
Six government drug control laboratories in the Middle East and North Africa will join together with the United States Pharmacopeial Convention in an effort to improve their capabilities to test the quality of drugs. The MENA Regional Laboratory Network aims to promote communication and exchange of information among participating countries, strengthen the performance and technical skill of the laboratories and their personnel, harmonize methods that facilitate approval of drugs across countries in the region, and help eliminate substandard and counterfeit drugs.
Researchers from The Australian National University have identified unique molecular signals in the body that could hold the key to developing a supplement capable of administering the health benefits of exercise to patients incapable of physical activity.
› Verified 2 days ago
Dr. Robert D Fusunyan, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 40 2nd Avenue, Suite 340, Waltham, MA 02451 Phone: 781-466-8967 Fax: 781-466-8987 | |
Dr. Beth Ann Mccabe, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 40 2nd Ave, Suite 400, Waltham, MA 02451 Phone: 781-522-9000 Fax: 617-735-9098 | |
Cynthia Sacco, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 245 Winter St, Waltham, MA 02451 Phone: 781-419-2709 | |
Myron B Peterson, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: Cato Ltd., 1100 Winter Street, Waltham, MA 02451 Phone: 617-484-2297 | |
Dr. Peter Tebet Greenspan, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 40 2nd Ave, Mass General West Medical Group Ste 400, Waltham, MA 02451 Phone: 781-487-4340 Fax: 781-487-4341 | |
Dr. Sarah Pritchett Zimmerman, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 40 2nd Ave Ste 400, Waltham, MA 02451 Phone: 781-487-4340 | |
James I Goldston, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 42 Weston St Ste 2a, Waltham, MA 02453 Phone: 781-747-8480 Fax: 949-577-4121 |